Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Keywords: CANCER ; CELLS ; EXPRESSION ; tumor ; TUMOR-CELLS ; CELL ; Germany ; KINASE ; THERAPY ; GENE ; GENE-EXPRESSION ; PROTEIN ; cell line ; TUMORS ; LINES ; DNA ; INFECTION ; REDUCTION ; CELL-LINES ; PHOSPHORYLATION ; treatment ; PARTICLES ; virus ; ISOFORM ; gene expression ; PROMOTER ; DECREASE ; ELEMENTS ; NUMBER ; CELL-LINE ; LINE ; TRANSFORMATION ; GLUCOSE ; FLUORESCENCE ; REGULATORY ELEMENTS ; adeno-associated virus ; ADENOASSOCIATED VIRUS ; VIRUS THYMIDINE KINASE ; TUMOR-CELL-LINES ; HIGH-LEVEL ; HaCaT ; Ras ; THYMIDINE KINASE ; SRC ONCOGENE ; ADENOASSOCIATED VIRUS VECTORS ; CYSTIC-FIBROSIS ; glucose transporter promoter,HSV thymidine kinase,suicide gene,AAV
    Abstract: In order to achieve tumor-specific targeting of adeno-associated virus (AAV)-mediated gene expression, the promoter of the glucose transporter isoform 1 (GLUT1) gene was cloned upstream of the enhanced green fluorescence protein (EGFP) and the herpes simplex virus thymidine kinase (HSVtk) gene. FACS analysis performed at 48 h after transient infection with rAAV/cytomegalovirus (CMV)egfp viral particles revealed an increase of fluorescence in all the cell lines tested. However, EGFP expression under control of the GLUT1 promoter element (rAAV/GTI-1.3egfp) was limited to the tumor cells and oncogene-transformed cells. Evidence for phosphorylation of the HSVtk substrates ganciclovir (GCV) and I-125-deoxycytidine was found in all transfected tumor cell lines compared to noninfected controls (HCT116: 111%; MH3924A: 130%; HaCaT-RT3: 257% increase), but not in HaCaT and HUVEC cells. Furthermore, tumor cells and the oncogene-transformed (ras) cell line HaCaT-RT3 showed a GCV-induced reduction in cell number (HCT116:-71%; MH3924A:-43% and HaCaT-RT3:-31%). No statistically relevant cytotoxic effect was observed in HaCaT (6% decrease) and HUVEC cells (2% decrease). Furthermore, a reduction of H-3-thymidine incorporation into the DNA was seen after treatment with GCV (HCT116: 38%; MH3924A: 33% and HaCaT-RT3: 37% decrease). In a therapy study of HSVtk-expressing tumors with GCV, we achieved total tumor remission
    Type of Publication: Journal article published
    PubMed ID: 14681725
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: CANCER ; CELLS ; EXPRESSION ; IN-VITRO ; IN-VIVO ; THERAPY ; GENE ; gene therapy ; LINES ; NUCLEAR-MEDICINE ; TIME ; TRANSDUCTION ; ACTIVATION ; RAT ; PROSTATE-CANCER ; TRANSFORMATION ; GLUCOSE ; ESTABLISHMENT ; sodium iodide symporter ; glucose transporter promoter ; SODIUM-IODIDE SYMPORTER ; SRC ONCOGENE ; THYROID-CELLS
    Abstract: Targeted transfer of a functionally active sodium iodide symporter (NIS) into tumour cells may be used for radioiodine therapy of cancer. Therefore, we investigated radioiodine uptake in a hepatoma cell line in vitro and in vivo after transfer of the sodium iodide symporter (hNIS) gene under the control of a tumour-specific regulatory element, the promoter of the glucose transporter 1 gene (GTI-1.3). Employing a self- inactivating bicistronic retroviral vector for the transfer of the hNIS and the hygromycin resistance genes, rat Morris hepatoma (MH3924A) cells were infected with retroviral particles and hNIS-expressing cell lines were generated by hygromycin selection. I-125(-) uptake and efflux were determined in genetically modified and wild type hepatoma cells. In addition, the iodide distribution in rats bearing wild type and genetically modified hepatomas was monitored. hNIS-expressing MH3924A cell lines accumulated up to 30 times more iodide than wild type hepatoma cells, with a maximal iodide uptake after 30 min incubation time. Competition experiments in the presence of sodium perchlorate revealed a decrease in the iodide uptake (80-84% decrease). Moreover, ouabain led to a loss of accumulated I- (81% decrease) whereas 4,4'-diisothiocyano-2,2'-disulphonic acid stilbene (DIDS) increased the I- uptake into cells (87% increase). However a rapid efflux of the radioactivity (70%) was observed 20 min after I-125-containing medium had been replaced by non- radioactive medium. Lithium had no significant effect on iodide efflux. In rats, the hNIS-expressing tumours accumulated 22 times more iodide than the contralateral wild type tumour. In accordance with the in vitro data, we also observed a rapid efflux of the radioactivity out of the tumour in vivo. Dosimetric calculations resulted in an absorbed dose of 85 mGy in the wild type tumour and 830 mGy in the hNIS-expressing tumour after administration of 18.5 MBq I-131. In conclusion, transduction of the hNIS gene under the control of the GLUT1 promoter element induces iodide transport in Morris hepatoma cells in vitro and in vivo. However, for therapeutic application additional conditions need to be defined which inhibit the iodide efflux out of the tumour cells
    Type of Publication: Journal article published
    PubMed ID: 12541134
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    Keywords: CANCER ; CELLS ; EXPRESSION ; tumor ; carcinoma ; human ; THERAPY ; GENE ; TUMORS ; gene therapy ; LINES ; NUCLEAR-MEDICINE ; TIME ; TRANSDUCTION ; RAT ; RATS ; treatment ; PROSTATE-CANCER ; THYROID-CARCINOMA ; KINETICS ; CARCINOMA CELL-LINE ; EXPERIMENTAL I-131 THERAPY ; human sodium iodide transporter ; LITHIUM ; NA+/I SYMPORTER ; prostate carcinoma ; RADIOIODINE THERAPY ; sodium iodide symporter ; SODIUM/IODIDE SYMPORTER
    Abstract: Transfer of the sodium iodide symporter (hNIS) has been proposed as a new principle of cancer gene therapy. Using clinically relevant doses of I-131 for the treatment of NIS- expressing prostate carcinoma cells, we investigated the kinetics and the absorbed doses obtained in these tumors. hNIS- expressing cell lines accumulated up to 200 times more iodide when compared to wild-type cells. However, a rapid efflux of the radioactivity (80%) occurred during the first 20 min after replacement of the medium. In rats, the hNIS-expressing tumors accumulated up to 20 times more iodide when compared to contralateral transplanted wild-type tumors. After 24 h and doses of 550, 1200 or 2400 MBq/m(2) hNIS-expressing tumors lost 89, 89 and 91% of the initial activity, respectively. Dosimetric calculations showed that 1200 MBq/m(2) resulted in 3+/-0.5 Gy (wild-type tumor 0.15+/-0.1 Gy) and 2400 MBq/m(2) resulted in 3.1+/-0.9 Gy (wild-type tumor 0.26+/-0.02 Gy). Although transduction of the hNIS gene induces iodide transport in rat prostate adenocarcinoma a rapid efflux occurs, which leads to a low absorbed dose in genetically modified tumors. With regard to a therapeutic application additional conditions need to be defined leading to iodide trapping
    Type of Publication: Journal article published
    PubMed ID: 12704416
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    Keywords: CANCER ; CELLS ; EXPRESSION ; GROWTH ; tumor ; carcinoma ; CELL ; Germany ; human ; IN-VIVO ; INHIBITION ; THERAPY ; VIVO ; SYSTEM ; TOOL ; HEPATOCELLULAR-CARCINOMA ; GENE ; GENE-EXPRESSION ; EFFICIENCY ; cell line ; TUMORS ; gene therapy ; MICE ; TRANSDUCTION ; gene transfer ; GENE-TRANSFER ; INFECTION ; murine ; treatment ; PARTICLES ; virus ; ELEMENT ; TRANSGENIC MICE ; gene expression ; VECTORS ; VECTOR ; PROMOTER ; ELEMENTS ; REQUIRES ; NUDE-MICE ; CELL-LINE ; LINE ; EFFICIENT ; MELANOMA ; GROWTH-INHIBITION ; Jun ; MALIGNANT-MELANOMA ; malignant melanoma ; GENE-THERAPY ; RECOMBINANT ADENOASSOCIATED VIRUS ; THYMIDINE KINASE GENE ; REGULATORY ELEMENTS ; adeno-associated virus ; ADENOASSOCIATED VIRUS ; nude mice ; HIGH-LEVEL ; TISSUE-SPECIFIC EXPRESSION ; growth inhibition ; CYTOTOXICITY ; F ; ENHANCER ; RECOMBINANT ; GANCICLOVIR ; suicide gene therapy ; HUMAN-MELANOMA ; THERAPIES ; GLIOMA-CELLS ; MELANOMA-CELLS ; ADENOASSOCIATED VIRUS VECTORS ; REPORTER GENE ; NONDIVIDING CELLS ; human melanoma ; herpes simplex virus thymidine kinase ; melanoma inhibitory activity
    Abstract: Suicide gene therapy of malignant melanoma essentially requires efficient gene transfer and highly selective therapeutic gene expression. To achieve this, recombinant adeno-associated virus (rAAV) particles were constructed containing the tissue-specific promoter of the human melanoma inhibitory activity (hMIA) gene combined with four copies of the enhancer element of the murine tyrosinase gene. Three melanoma and one cervix carcinoma cell line were infected with rAAV particles carrying a reporter gene under control of the enhancer/hMIA promoter in order to determine transcriptional activity and specificity of this system. Viral particles containing the enhancer/hMIA promoter mediated reporter gene activity only in melanoma cells, whereas infection with a cytomegalovirus (CMV)-based promoter construct induced unspecific gene expression. Correspondingly, transient transduction with viral particles bearing the HSVtk gene under the control of the enhancer/MIA promoter elements followed by treatment with ganciclovir (GCV) resulted in growth inhibition only in melanoma cells, whereas the CMV promoter-based construct induced unspecific cytotoxicity. In vivo experiments in nude mice demonstrated that tumors originating from human melanoma cells disappeared after stable, but not transient transduction with vectors bearing the HSVtk gene under the control of the enhancer/hMIA promoter in response to GCV application. In face of higher transduction efficiency, these rAAV particles might therefore be a useful tool for suicide gene therapy of malignant melanoma
    Type of Publication: Journal article published
    PubMed ID: 15118759
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...